Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call …

19 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and …

CouponFollow Extension

22%
OFF

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call …

2 weeks from now

19 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and …

yahoo.com

22%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops …

2 weeks from now

1 day ago · Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues …

yahoo.com

80%
OFF

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call …

2 weeks from now

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) secured additional commercial coverage and two large Medicare contracts, covering more than 80% of patient lives. The company launched a …

investing.com

22%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue ...

2 weeks from now

2 days ago · Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers …

zacks.com

$0.88
OFF

Tarsus Pharmaceuticals (TARS) Earnings Date And Reports 2024

2 weeks from now

1 day ago · Tarsus Pharmaceuticals (TARS) Earnings Date, Estimates & Call Transcripts. Tarsus Pharmaceuticals released Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.88, …

marketbeat.com

18%
OFF

Tarsus Q3 Revenue Jumps 18% To $48.1M As XDEMVY Sales …

2 weeks from now

1 day ago · IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and …

stocktitan.net

$48
OFF

Earnings Call: Tarsus Reports Record Sales For XDEMVY In Q3 2024

2 weeks from now

1 day ago · Tarsus Pharmaceuticals, Inc. (TARS) announced robust third-quarter results for 2024, with a record $48 million in net product sales for XDEMVY, an eye care treatment for demodex …

investing.com

FAQs about Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call … Coupon?

How much did Tarsus pharmaceuticals (Tars) earn in Q3 2024?

SA Transcripts 150.4KFollowers Follow Q3: 2024-11-13 Earnings Summary Play Call10-Q EPS of -$0.61 beats by $0.31 | Revenue of $48.12M(2,471.78% Y/Y)beats by $4.94M Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET ...

Who is in Tarsus pharmaceuticals Q3 2024 conference call?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants ...

How did Tarsus pharmaceuticals (Tars) perform in the quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. ...

How many times has Tarsus pharmaceuticals surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates four times. Tarsus Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $48.12 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 11.34%. ...

Who is Tarsus pharmaceuticals?

Here is a breakdown of the information Tarsus Pharmaceuticals, Inc. presented to its investors. Tarsus Pharmaceuticals, Inc. is a company dedicated to revolutionizing treatment through proven science and new technology, with a primary focus on eye care, dermatology, and infectious disease prevention. ...

How much did Tarsus pharmaceuticals (Tars) lose?

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 32.22%. ...